Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label rilzabrutinib study in IgG4-related disease
2022-002959-18Phase 2Terminated
- Sponsor
- Principia Biopharma
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rilzabrutinib in IgG4-related disease (IgG4-RD) (2 arms), sponsored by Principia Biopharma. Primary endpoint: Proportion of participants without disease flare for at least 24 consecutive weeks following first dose. Started Dec 2022; status: terminated.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on 2022-002959-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002959-18.